dystocia in the state of California between 2007 and 2011 using linked vital statistics and ICD -9 data. We stratified brachial plexus injuries by maternal BMI and parity. We used chi-square tests to compare outcomes and multiple logistic regression to estimate adjusted odds ratio (aOR) while controlling for birth weight. RESULTS: In our cohort of 1,362,142 pregnancies, 1,717 fetuses were affected by brachial plexus injuries. The risk for brachial plexus injury in deliveries unaffected by shoulder dystocia increased with BMI. This effect persisted when stratifying by parity. Multiparous women categorized as underweight, normal, overweight, obese II, morbid obesity and superobese had increased rates of brachial plexus injury when compared to nulliparous women. The superobese group was associated with the highest rates of brachial plexus injury and had an odds ratio of 2.28 (95% CI: 1.01-5.12). CONCLUSION: Pre-pregnancy BMI is associated with an increasing risk of brachial plexus injuries, even in pregnancies unaffected by shoulder dystocia. This data suggests prenatal interventions targeting weight management may be beneficial in reducing brachial plexus injuries in all deliveries. Houston Fertility Institute, Houston, TX OBJECTIVE: While women undergoing in vitro fertilization (IVF) are known to have higher risks for multiple perinatal morbidities, the degree to which the stage of embryo transfer imparts risk is presently unknown. The aims of the current study were to evaluate the risk of adverse obstetric and neonatal outcomes among women who underwent IVF comparing cleavage versus blastocyst stage transfer. STUDY DESIGN: This is a retrospective cohort study using a multihospital, single academic institution database from May 2014 e April 2017. Deliveries of pregnancies conceived by IVF with data available for stage of transfer were included. Deliveries following embryo transfer on days other than 3 or 5 were excluded. The cohort was grouped by cleavage (day 3) versus blastocyst (day 5) embryo transfer. Univariate analysis was performed for baseline characteristics and obstetric and neonatal outcomes. Logistic regression analysis was performed to control for potential confounders. RESULTS: A total of 264 deliveries (n¼338 neonates) were included; 46 cleavage stage transfers (17%, n¼60 neonates) and 218 blastocyst transfers (83%, n¼278 neonates). There were no differences between the two groups in terms of maternal age, ethnicity/race, method of payment, BMI, tobacco use, parity, preexisting diabetes or hypertension, or major congenital anomalies (P>0.05). The mean number of embryos transferred was higher in the cleavage group (1.9 vs. 1.6, P¼0.037), and the proportion of frozen transfers was lower in the cleavage group (41.3% vs. 69.7%, P<0.001). On univariate analysis, rates of all outcomes were similar between the two groups (P>0.05). Analysis adjusted for multiple gestations, number of embryos transferred, and frozen transfer demonstrated no significant difference in rates of preeclampsia, cesarean delivery, preterm birth, low birthweight, and NICU admission (P>0.05).
CONCLUSION: Blastocyst transfer yields higher pregnancy rates with fewer embryos transferred and has become the preferred stage for transfer. However, it is important to evaluate if blastocyst transfer confers additional pregnancy risks. We found no association between stage of transfer and risk of adverse obstetric and neonatal outcomes for deliveries following IVF. This information is likely to be useful for counseling patients and establishing IVF standards of care.
836 Extracorporeal membrane oxygenation in pregnant and postpartum women: a ten-year cohort
Carolyn M. Webster, Tracy Manuck
University of North Carolina, Chapel Hill, NC OBJECTIVE: Extracorporeal membrane oxygenation (ECMO) is a lifesaving therapy for severe, reversible cardiopulmonary failure. ECMO survival in the general adult population is 50-70%, and available data on ECMO use in obstetric patients is reassuring, with survival rates approaching 80%; however, <100 cases of peripartum ECMO use are described in the literature. We sought to quantify peripartum maternal survival of ECMO in a contemporary cohort at a single tertiary institution. STUDY DESIGN: All women, aged 14-54yo, who underwent ECMO at our institution between January 1, 2008 and December 31, 2017 were identified using a query of hospital encounters for ECMOrelated CPT codes. Chart review was utilized to determine peripartum status (pregnant or < 6 weeks postpartum). Clinical characteristics as well as maternal and fetal outcomes are described. RESULTS: Fifty-four women of reproductive age underwent ECMO for cardiopulmonary failure during the study period. Of those, 9 (17%) were peripartum: 3 antepartum, 6 postpartum (Table 1) . Overall, peripartum maternal survival was 33% (vs. 51% of those not peripartum). The median maternal age was 24yo (range 19-39) , and the majority of women were non-smokers without underlying medical comorbidies. The most common indication for peripartum ECMO use was ARDS, present in 7 cases (78%), including 5 infectious etiologies and 2 cases of preeclampsia. The median number of days on ECMO was 6 (range 1-14), and there were no cases of obstetrical hemorrhage. Venovenous ECMO was utilized in all but one case, in which venoarterial ECMO was unsuccessful in resuscitating a postpartum patient with a massive pulmonary embolism and cardiac arrest. Among the 3 antepartum patients, maternal survival was 33%, fetal survival was 67%, and gestational age at ECMO initiation was 21, 29, and 30 weeks. There was one SVD of a live infant on ECMO. CONCLUSION: In this peripartum cohort of women who underwent ECMO, maternal survival was substantially lower than currently reported in the literature. Maternal survival was also substantially lower than that of the non-peripartum reproductive-aged women who underwent ECMO at our institution in the same time period. More information is needed on the safety and efficacy of peripartum ECMO use. 
